BR112018012177A2 - ?moduladores de hidantação de canais kv 3? - Google Patents
?moduladores de hidantação de canais kv 3?Info
- Publication number
- BR112018012177A2 BR112018012177A2 BR112018012177A BR112018012177A BR112018012177A2 BR 112018012177 A2 BR112018012177 A2 BR 112018012177A2 BR 112018012177 A BR112018012177 A BR 112018012177A BR 112018012177 A BR112018012177 A BR 112018012177A BR 112018012177 A2 BR112018012177 A2 BR 112018012177A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydration
- modulators
- channel
- compounds
- prophylaxis
- Prior art date
Links
- 230000036571 hydration Effects 0.000 title 1
- 238000006703 hydration reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1522179.9A GB201522179D0 (en) | 2015-12-16 | 2015-12-16 | Novel compounds |
| PCT/GB2016/053958 WO2017103604A1 (en) | 2015-12-16 | 2016-12-16 | Hydantoin modulators of kv3 channels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018012177A2 true BR112018012177A2 (pt) | 2018-11-27 |
Family
ID=55274838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018012177A BR112018012177A2 (pt) | 2015-12-16 | 2016-12-16 | ?moduladores de hidantação de canais kv 3? |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200377485A1 (https=) |
| EP (1) | EP3390394B1 (https=) |
| JP (1) | JP7036725B2 (https=) |
| CN (1) | CN108430995A (https=) |
| BR (1) | BR112018012177A2 (https=) |
| GB (1) | GB201522179D0 (https=) |
| WO (1) | WO2017103604A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| WO2018109484A1 (en) | 2016-12-16 | 2018-06-21 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| TWI827706B (zh) | 2018-10-16 | 2024-01-01 | 英商奧堤凡尼治療股份有限公司 | 新穎化合物 |
| US12358901B2 (en) | 2018-10-16 | 2025-07-15 | Autifony Therapeutics Limited | KV3 modulators |
| AR116898A1 (es) | 2018-10-30 | 2021-06-23 | H Lundbeck As | DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVADORES DE CANALES DE POTASIO Kv3 |
| CN113692405A (zh) | 2019-04-26 | 2021-11-23 | H.隆德贝克有限公司 | 作为kv3钾通道激活剂的n-((杂芳基)甲基)-1-甲苯磺酰基-1h-吡唑-3-甲酰胺的衍生物用于治疗神经或精神障碍 |
| WO2020216919A1 (en) | 2019-04-26 | 2020-10-29 | H. Lundbeck A/S | ARYLSULFONYLTHIOPHENECARBOXAMIDES AND ARYLSULFONYLFURANCARBOXAMIDES AS Kν3 POTASSIUM CHANNEL ACTIVATORS |
| JP7522203B2 (ja) * | 2020-02-06 | 2024-07-24 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３モジュレーター |
| EP3901152A1 (en) * | 2020-04-23 | 2021-10-27 | F. Hoffmann-La Roche AG | Kv3 enhancers for the treatment of cognitive disorders |
| US20240327406A1 (en) | 2021-08-10 | 2024-10-03 | Autifony Therapeutics Limited | Potassium channel modulators |
| EP4630117A1 (en) | 2022-12-06 | 2025-10-15 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6299383A (ja) * | 1985-10-28 | 1987-05-08 | Tokuyama Soda Co Ltd | エ−テル化合物の製造方法 |
| EP1534276B1 (en) | 2002-09-05 | 2008-11-05 | Medivir AB | Non-nucleoside reverse transcriptase inhibitors |
| US20050080100A1 (en) | 2003-10-09 | 2005-04-14 | Pfizer Inc | Pyridylamino compounds and methods of use thereof |
| EP1845087A1 (en) | 2006-04-14 | 2007-10-17 | Mutabilis SA | Hydroxyphenyl derivatives and biological applications thereof |
| JP6112486B2 (ja) | 2010-04-27 | 2017-04-12 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| EP2649066B1 (en) * | 2010-12-06 | 2015-10-21 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| US20120316182A1 (en) * | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2736908A1 (en) | 2011-07-27 | 2014-06-04 | Glaxo Group Limited | Bicyclic pyrimidone compounds |
| EP2852588B8 (en) | 2012-05-22 | 2018-01-10 | Autifony Therapeutics Limited | Hydantoin derivatives as kv3 inhibitors |
| WO2013182851A1 (en) * | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| WO2013182581A1 (en) * | 2012-06-06 | 2013-12-12 | Evonik Oil Additives Gmbh | Fuel efficient lubricating oils |
| CN105612152A (zh) * | 2013-08-26 | 2016-05-25 | 普渡制药公司 | 氮杂螺[4.5]癸烷衍生物及其用途 |
-
2015
- 2015-12-16 GB GBGB1522179.9A patent/GB201522179D0/en not_active Ceased
-
2016
- 2016-12-16 EP EP16816359.0A patent/EP3390394B1/en not_active Not-in-force
- 2016-12-16 US US16/061,557 patent/US20200377485A1/en not_active Abandoned
- 2016-12-16 BR BR112018012177A patent/BR112018012177A2/pt not_active IP Right Cessation
- 2016-12-16 JP JP2018531529A patent/JP7036725B2/ja not_active Expired - Fee Related
- 2016-12-16 WO PCT/GB2016/053958 patent/WO2017103604A1/en not_active Ceased
- 2016-12-16 CN CN201680074553.9A patent/CN108430995A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7036725B2 (ja) | 2022-03-15 |
| CN108430995A (zh) | 2018-08-21 |
| EP3390394A1 (en) | 2018-10-24 |
| JP2019502696A (ja) | 2019-01-31 |
| WO2017103604A1 (en) | 2017-06-22 |
| US20200377485A1 (en) | 2020-12-03 |
| EP3390394B1 (en) | 2022-05-25 |
| GB201522179D0 (en) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018012177A2 (pt) | ?moduladores de hidantação de canais kv 3? | |
| EP3545647A4 (en) | REGULATION OF CONFIDENT BLOCKCHAIN TRANSACTIONS | |
| UY37381A (es) | Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos | |
| MX2019014041A (es) | Inhibidores pirazolicos de magl. | |
| MX383652B (es) | Moduladores de la vía de estrés integrada. | |
| MX384792B (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| EA201891344A1 (ru) | Новые агонисты рецептора апелина и способы применения | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| AU2016278853A8 (en) | Petrolatum-based compositions comprising cationic biocides | |
| MX383880B (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| CL2016000106A1 (es) | Sulfonamidas como moduladores de canales de sodio. | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| MX384833B (es) | Inhibidores de tirosina quinasa de bruton | |
| CR20200089A (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
| MX389001B (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| MX391040B (es) | Formulacion de alta concentracion. | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| CR20160047A (es) | Inhibidores de rorc2 y sus métodos de uso | |
| MX395032B (es) | Ciertos inhibidores de la proteína quinasa. | |
| MX385578B (es) | Moduladores de canales de kv3 para tratar dolor. | |
| CO2019014647A2 (es) | Composiciones inmunogénicas | |
| MX374728B (es) | MODULADORES DE ROR GAMMA (RORy). | |
| CR20190536A (es) | Inhibidores pirazólicos de magl |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2753 DE 10-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |